GATTEX® (teduglutide)

For people 1 year of age and older with SHORT BOWEL SYNDROME (SBS) who are dependent on parenteral support (PS).
GATTEX® (teduglutide) for subcutaneous injection is a prescription medicine used in adults and children 1 year of age and older with short bowel syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding, also known as parenteral support. It is not known if GATTEX is safe and effective in children under 1 year of age.
GATTEX works like a natural gut hormone produced by your own body, known as glucagon-like peptide-2 or GLP-2. In a study of adults, GATTEX was proven to help the remaining intestine absorb more fluid.*
GATTEX may cause serious side effects including making abnormal cells grow faster, polyps in the intestines, blockage of the bowel or intestines, swelling or inflammation, blockage of your gallbladder or pancreas, and fluid overload.
For additional safety information, click here for full Prescribing Information and Medication Guide, and discuss any questions with your doctor.
*The ability of GATTEX to improve the amount of fluid absorbed by the intestines was studied in 17 adult subjects with SBS. Participants in the study received GATTEX for 21 days. All the participants in this study knew they were taking GATTEX. They each took daily doses of either 0.03, 0.10, or 0.15 mg/kg by subcutaneous injection, which is 0.6 to 3 times the recommended dose. The recommended dose is 0.05 mg/kg/day. The injections were administered under the skin in the stomach area, or abdomen. All of the doses studied, except for the 0.03 mg/kg once-daily dose, resulted in enhanced absorption of fluid by the intestines — approximately 750 to 1000 mL per day — and increased the surface area of the intestines. The ability of GATTEX to improve intestinal absorption in children has not been investigated.